Shots:

• Teva and Celltrion launch Truxima (rituximab-abbs) injection as the first biosimilar referencing Roche’s Rituxan (rituximab) to be available in the US by the week of November 11- addressing the unmet medical needs of the patients in the US
• The approval of Truxima is based on clinical/ nonclinical- pharmacology- immunogenicity- clinical efficacy and safety data. Truxima is being made available via primary wholesalers at a WAC of $845.55 for 100mg vial and $4227.75 for 500mg vial with its actual cost to be lower than WAC
• Truxima is the first rituximab biosimilar and has received FDA’s approval to match all the reference product’s oncology indications for NHL and CLL in May’2019. Additionally- Celltrion and Teva have a pending submission of Truxima for RA- GPA- & MPA with a license to expand its label to include these indications in Q2’20

Click here to­ read full press release/ article | Ref: Businesswire | Image: Teva